Biomedical Occupation or Discipline
Federal Judge Rules NIH Grant Terminations Illegal, Orders Restoration of Hundreds of Grants
NIH; grant terminations; federal judge; racial discrimination; DEI; gender identity; Trump administration; biomedical research; public health; LGBTQ+; health disparities
Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration
Fauna Brain; agentic AI; drug discovery; comparative genomics; Lilly collaboration; multi-agent system; pharmaceutical research; AI platform
BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal
BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine
Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines
Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership
Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs
Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal
Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights
ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines
All innuendo and conspiracy: RFK Jr.’s vaccine advisory overhaul undermines vaccine confidence, experts say
RFK Jr.; vaccine advisory; ACIP; public health; conspiracy; confidence; overhaul
23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron
23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics
Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey
cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine
Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies
Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration